Three-shot combo? Pfizer, BioNTech roll COVID-19 booster trial as real world data back first vaccine

As Pfizer and BioNTech start testing whether a third dose of their COVID-19 shot can help fend off new coronavirus variants, a massive real-world study has confirmed that its first, two-dose regimen is 94% effective. The third-dose study now underway will gauge the effects of that follow-up dose on circulating and new COVID-19 virus variants. At the same time, the companies are in talks with the FDA and EMA about studying a new booster specifically designed to tackle new variants. They're hoping to validate 'future modified mRNA vaccines with a regulatory pathway similar to what is currently in place for flu vaccines,” according to a press release.